I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on December 15, 2005.

Frank C. Eisenschenk, Ph.D., Patent Attorney

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Examining Group 1646 Patent Application Docket No. G-029US04DIV Serial No. 10/072,159

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Gyan Chandra

Art Unit

1646

Applicants

Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin

Serial No.

10/072,159

Filed

Conf. No.

February 5, 2002

For

2627

Lipoprotein-Regulating Medicaments

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited reference is enclosed. However, Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449A/PTO					Complete if Known		
				.nr		Application Number	10/072,159	
INFORMATION DISCLOSURE						Filing Date	February 5, 2002	
	STATEMENT BY APPLICANT				•	First Named Inventor	Bernard Bihain	
	(use as many sheets as necessary)					Art Unit	1646	
						Examiner Name	Gyan Chandra	
	Sheet	1	of	2		Attorney Docket Number	G-029US04DIV	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	U1	US-6,967,091	11-22-2005	Fruebis <i>et al</i> .	All			
	U2	US-6,867,189	03-15-2005	Lucas <i>et al</i> .	All			
	U3	US-6,566,332	05-20-2003	Fruebis <i>et al</i> .	All			
	U4	US-2003-0215836	11-20-2003	Young <i>et al.</i>	All			
	U5	US-2005-0069971	03-31-2005	Lucas et al.	All			
	U6	US-2005-0054565	03-31-2005	Lucas et al.	All			
	U7	US-2005-0003997	01-06-2005	Lucas <i>et al</i> .	All			
	U8	US-2003-0224501	12-04-2003	Young <i>et al.</i>	All			
	U9	US-6,946,444	09-20-2005	Bihain <i>et al.</i>	All			
	U10	US-6,344,441	02-05-2002	Bihain <i>et al.</i>	All			
	U11	US-6,566,332	05-20-2003	Fruebis <i>et al</i> .	All			
	U12	US-2004-0067881-A1	04-08-2004	Fruebis <i>et al</i> .	All			
	U13							

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [€]	
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	F1						
	F2						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

or namber.				Complete if Known		
	e for form 1449B/PT	-	OCUDE	Application Number	10/072,159	
	RMATION I			Filing Date	February 5, 2002	
STAT	EMENT BY	' APF	PLICANT	First Named Inventor	Bernard Bihain	
			200001	Group Art Unit	1646	
(us	se as many sheet	s as nec	essary)	Examiner Name	Gyan Chandra	
Sheet	2	of	2	Attorney Docket Number	G-029US04DIV	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	R1	U.S. Patent Application Serial No. 11/132,814, filed May 19, 2005, claims only.	
	R2	Database Entrez Nucleotides, Accession No. BAA08227, a novel adipose specific collagen-like factor, February 10, 1999.	
	R3	Database Entrez Nucleotides, Accession No. D45371, Human apM1 mRNA, February 10, 1999.	
	R4	Online Mendelian Inheritance in Man database; Adipocyte, C1Q, and Collagen Domain Containing; ACDC; accessed August 24, 2005.	
	R5	BLOOMGARDEN, Z. T. "Obesity, Hypertension, and Insulin Resistance" <i>Diabetes Care</i> , November 2002, pp. 2088-2097, Vol. 25, No. 11.	
•	R6	STEINBERGER, J. et al. "Obesity, Insulin Resistance, Diabetes, and Cardiovascular Risk in Children" Circulation, 2003, Vol. 107, pp. 1448-1453.	
	R7	DE JONGH, R. T. et al. "Impaired Microvascular Function in Obesity" Circulation, 2004, pp. 2529-2535, Vol. 109.	
	R8		
	R9		
	R10		
	R11		
	R12		Ī
	R13		T

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.